Jorveza 1 mg compresse orodispersibili ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
98好酸球性消化管疾患1

98. 好酸球性消化管疾患


臨床試験数 : 172 薬物数 : 149 - (DrugBank : 39) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 135
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-003516-39-IT
(EUCTR)
09/07/202117/08/2021A phase III clinical study in adult and adolescent patients with eosinophilic inflammation of the gullet to prove superiority compared to placebo of an episodic and/or a continuous 48-week treatment with budesonide orodispersible tablets for maintaining remissionDouble-blind, randomized phase III trial in adult and adolescent patients with eosinophilic esophagitis to prove superiority compared to placebo of an episodic and/or a continuous 48-week treatment with budesonide orodispersible tablets for maintaining clinico-histological remission - Episodic and continuous treatment with budesonide orodispersible tablets versus placebo for maintena Maintenance of remission in eosinophilic esophagitis
MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Trade Name: Jorveza 1 mg compresse orodispersibili
Product Name: Budesonide 1 mg compresse orodispersibili
Product Code: [BUL 1 mg]
INN or Proposed INN: BUDESONIDE
Trade Name: Jorveza 0.5 mg compresse orodispersibili
Product Name: Budesonide 0.5 mg compresse orodispersibili
Product Code: [BUL 0.5 mg]
INN or Proposed INN: BUDESONIDE
DR. FALK PHARMA GMBHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
110Phase 3Spain;Germany;Switzerland;Italy